Amylin's long-delayed diabetes drug gets FDA nod
Friday, January 27, 2012 - 16:00
in Health & Medicine
WASHINGTON (AP) -- Federal health regulators have approved Amylin Pharmaceutical's long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's current offering, Byetta....